Botulinum toxin type A for the treatment of glabellar lines in Chinese: a double-blind, randomized, placebo-controlled study.
BACKGROUND
This is the first well-controlled study of the use of botulinum toxin type A (BoNTA) for glabellar lines in China.


OBJECTIVE
To evaluate the safety and efficacy of BoNTA in the treatment of glabellar lines in Chinese subjects.


METHODS
A total of 227 subjects received a single treatment in a 3:1 randomization ratio of BoNTA (20 U):placebo and were observed for 120 days after injection. Effective outcome measures included investigator's rating of wrinkle severity at maximum frown and rest and subjects' global assessment and self-perception of age.


RESULTS
A significantly higher responder rate at maximum frown, ranging from 94.1% at day 30 to 52.9% at day 120, was noted in the BoNTA group. The proportion of subjects with none or mild glabellar lines at rest was 66.7% in the BoNTA group at day 30. Most (95.3%) of the subjects treated with BoNTA reported better than 50% improvement at day 30, and self-perception of age was less than chronological age. There were no statistically significant differences in adverse events reported between the two groups (p=.06).


CONCLUSIONS
A single treatment of 20 U of BoNTA was effective and safe in reducing glabellar lines in Chinese subjects.
Wu
Yan
Y
Department of Dermatology, Peking University First Hospital, Beijing, China. adelewu@medmail.com.cn
Zhao
Guang
G
Li
Hengjin
H
Zheng
Zhizhong
Z
Zhong
Shaomin
S
Yang
Zhiyong
Z
Feng
Zheng
Z
Yang
Qinping
Q
Zhu
Xuejun
X
D000328:Adult; D044466:Asian People; D019274:Botulinum Toxins, Type A / Q000008:administration & dosage*; D002681:China; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007273:Injections, Intramuscular; D008297:Male; D009465:Neuromuscular Agents / Q000008:administration & dosage*; D011446:Prospective Studies; D015595:Skin Aging / Q000187:drug effects*; D016896:Treatment Outcome
D009465:Neuromuscular Agents; D019274:Botulinum Toxins, Type A